In the original version of this article,the legend to Figure 1 was incorrect.The corrected legend is given below.Fig.1 A Location of the primers in SARS-CoV-2 genome.B Sequence comparison among seven human coronavirus...In the original version of this article,the legend to Figure 1 was incorrect.The corrected legend is given below.Fig.1 A Location of the primers in SARS-CoV-2 genome.B Sequence comparison among seven human coronaviruses(SARS-CoV-2,SARS-CoV,MERS-CoV,HCoVOC43,HCoV-HKU-1,HCoV-NL63 and HCoV-229E).C Cross-reactivity test of the novel SARS-CoV-2 RTLAMP assay to other common respiratory viruses.Tested common respiratory viruses include HCoV-HKU-1,HCoV-NL63,HCoV-OC43,HCoV-229E,influenza A,B,and C viruses,parainfluenza viruses type 1-3,enterovirus,respiratory syncytial virus A and B groups,human rhinovirus,human metapneumovirus,adenovirus and bocavirus.展开更多
Dear Editor,Since early December 2019, a large outbreak of pneumonia caused by a novel coronavirus(COVID-19) had emerged in Wuhan, China(Wu et al. 2020 a, b;Zhou et al. 2020;Zhu et al. 2020;Jiang and Shi 2020). Simila...Dear Editor,Since early December 2019, a large outbreak of pneumonia caused by a novel coronavirus(COVID-19) had emerged in Wuhan, China(Wu et al. 2020 a, b;Zhou et al. 2020;Zhu et al. 2020;Jiang and Shi 2020). Similar to severe acute respiratory syndrome coronavirus(SARS-CoV) and Middle East respiratory syndrome coronavirus(MERS-CoV),the new coronavirus also belongs to Betacoronavirus。展开更多
Inactivated coronavirus disease 2019(COVID-19)vaccines such as CoronaVac and BBIBP-CorV have been widely used in China.However,more investigation is still needed to understand antibodies'duration and effectiveness...Inactivated coronavirus disease 2019(COVID-19)vaccines such as CoronaVac and BBIBP-CorV have been widely used in China.However,more investigation is still needed to understand antibodies'duration and effectiveness against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variants in the real world.In this study,575 participants who had been vaccinated with two or three doses of the inactivated vaccine were recruited.Serum samples were collected and tested for anti-spike IgG and neutralizing antibodies against SARS-CoV-2(original strain,Dela,and Omicron).Unsurprisingly,a third dose of the vaccine significantly enhanced antibody responses against SARS-CoV-2 and its variants.However,despite a booster dose,the neutralizing antibody levels against Omicron,particularly the BA.5.2 subvariant,remained low.There was no sex bias,but an age bias was observed.Notably,the predominant IgG subclass antibodies were IgG1 and IgG2,with a much lower level of IgG4.After the booster shot,the ratio of IgG4 to IgG1 significantly increased.The observation of IgG1 to the IgG4 class switch after repeated inactivated vaccinations underscores the importance of continuous monitoring of subclass antibody responses.Further clinical investigations are required to understand the implications of this class switch for optimizing immunization strategies.展开更多
文摘In the original version of this article,the legend to Figure 1 was incorrect.The corrected legend is given below.Fig.1 A Location of the primers in SARS-CoV-2 genome.B Sequence comparison among seven human coronaviruses(SARS-CoV-2,SARS-CoV,MERS-CoV,HCoVOC43,HCoV-HKU-1,HCoV-NL63 and HCoV-229E).C Cross-reactivity test of the novel SARS-CoV-2 RTLAMP assay to other common respiratory viruses.Tested common respiratory viruses include HCoV-HKU-1,HCoV-NL63,HCoV-OC43,HCoV-229E,influenza A,B,and C viruses,parainfluenza viruses type 1-3,enterovirus,respiratory syncytial virus A and B groups,human rhinovirus,human metapneumovirus,adenovirus and bocavirus.
基金supported by the grants from the National Science and Technology Major Project of China (2019YFC1200603, 2017ZX10103009-002)。
文摘Dear Editor,Since early December 2019, a large outbreak of pneumonia caused by a novel coronavirus(COVID-19) had emerged in Wuhan, China(Wu et al. 2020 a, b;Zhou et al. 2020;Zhu et al. 2020;Jiang and Shi 2020). Similar to severe acute respiratory syndrome coronavirus(SARS-CoV) and Middle East respiratory syndrome coronavirus(MERS-CoV),the new coronavirus also belongs to Betacoronavirus。
基金the Key Project of the Natural Science Foundation of Tianjin,China(No.20JCZDJC00090).The funders played no role in the study design,data collection and analysis,decision to publish,or manuscript preparation.
文摘Inactivated coronavirus disease 2019(COVID-19)vaccines such as CoronaVac and BBIBP-CorV have been widely used in China.However,more investigation is still needed to understand antibodies'duration and effectiveness against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variants in the real world.In this study,575 participants who had been vaccinated with two or three doses of the inactivated vaccine were recruited.Serum samples were collected and tested for anti-spike IgG and neutralizing antibodies against SARS-CoV-2(original strain,Dela,and Omicron).Unsurprisingly,a third dose of the vaccine significantly enhanced antibody responses against SARS-CoV-2 and its variants.However,despite a booster dose,the neutralizing antibody levels against Omicron,particularly the BA.5.2 subvariant,remained low.There was no sex bias,but an age bias was observed.Notably,the predominant IgG subclass antibodies were IgG1 and IgG2,with a much lower level of IgG4.After the booster shot,the ratio of IgG4 to IgG1 significantly increased.The observation of IgG1 to the IgG4 class switch after repeated inactivated vaccinations underscores the importance of continuous monitoring of subclass antibody responses.Further clinical investigations are required to understand the implications of this class switch for optimizing immunization strategies.
